Biological barriers such as the blood-brain barrier, skin, and intestinal mucosal barrier play key roles in homeostasis, disease physiology, and drug delivery - as such, it is important to create representative models to improve understanding of barrier biology and serve as tools for therapeutic development. Microfluidic cell culture and organ-on-a-chip (OOC) systems enable barrier modelling with greater physiological fidelity than conventional platforms by mimicking key environmental aspects such as fluid shear, accurate microscale dimensions, mechanical cues, extracellular matrix, and geometrically defined co-culture. As the prevalence of barrier-on-chip models increases, so does the importance of tools that can accurately assess barrier integrity and function without disturbing the carefully engineered microenvironment. In this review, we first provide a background on biological barriers and the physiological features that are emulated through barrier models. Then, we outline molecular permeability and electrical sensing barrier integrity assessment methods, and the related challenges specific to barrier-on-chip implementation. Finally, we discuss future directions in the field, as well important priorities to consider such as fabrication costs, standardization, and bridging gaps between disciplines and stakeholders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/d3lc01027a | DOI Listing |
Alzheimers Dement
December 2024
Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Autonomous University of Barcelona, Barcelona, Catalonia, Spain.
Background: Alzheimer's and related disorders (ADRD) represent a range of neurodegenerative conditions characterized by abnormal protein deposits in the brain. Despite advances, there is a need for enhanced diagnostic and treatment approaches that acknowledge the diversity of ADRD. This project introduces the Alzheimer's and Related Disorders Multicenter Archive (ARMA), a collaborative platform with an advanced Electronic Data Capture (EDC) system linked to Electronic Medical Records (EMR) designed to refine ADRD diagnosis and natural history understanding, thus informing precision medicine.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disease that still has no cure. Different pathological processes contribute to the disease's development, such as the presence of amyloid beta (Aβ) plaques, neurofibrillary tangles (NFTs), glutamatergic excitotoxicity, oxidative stress, and neuroinflammation. Chalcones are polyphenolic compounds of natural origin with a wide range of biological activities, and emerging studies have reported neurotrophic activity, anti-inflammatory and antioxidant effects, and the inhibition of Aβ aggregation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.
Background: Black Americans (BAs), Hispanics/Latinos (H/Ls), and Africans (As) face a disproportionate burden of aging and Alzheimer's Disease and Related Dementias (AD/ADRD), coupled with underrepresentation in research. Further, researchers also report a lack of compliance on sensitive social determinants of health data for AD/ADRD research. For instance, the PRAPARE tool reports a low completion rate in community and clinical settings.
View Article and Find Full Text PDFBackground: A critical need to increase Alzheimer's disease (AD) screening exists given rising incidence, new disease-modifying treatments, and ill-equipped primary care settings. This study assessed the feasibility of a novel, community-based AD screening program to increase cognitive and retinal-based assessments.
Methods: An observational study, supported by the Davos Alzheimer's Collaborative, assessed the utility of leveraging community-based settings to increase rates of cognitive assessment (conducted by Alzheimer Society (AS) social workers [SWs]) and RetiSpec's AI-based eye test in optometry settings to detect biologic signatures of AD (plus participant survey).
Alzheimers Dement
December 2024
Washington University School of Medicine, Saint Louis, MO, USA.
Implementation of amyloid-lowering treatments in clinical care for early symptomatic Alzheimer disease (AD) raises many challenges. The Memory Diagnostic Center (MDC), the dementia specialty practice associated with Barnes-Jewish Hospital/Washington University School of Medicine (BJH/WUSM), has 16 clinicians (12 physicians and 4 advanced practice providers) who see over 2,000 patients with memory disorders per year. BJH is the academic flagship of BJC HealthCare (BJC), an integrated health system in St.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!